FOXO1 and amyotrophic lateral sclerosis: Inhibition of FOXO1 not only mitigated myogenic and metabolic abnormalities in ALS myoblast cells but also in other two MN disorders with muscle involvement, such as Spinal Muscular Atrophy (SMA) or Spinal Bulbar Muscular Atrophy (SBMA).